{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:43:46Z","timestamp":1785833026306,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10147-025-02785-3","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T13:26:50Z","timestamp":1750771610000},"page":"1562-1571","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["LH\u2013RH agonist monotherapy for androgen receptor-positive recurrent and\/or metastatic salivary gland cancer: a retrospective study"],"prefix":"10.1007","volume":"30","author":[{"given":"Takuma","family":"Kishida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Enokida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryutaro","family":"Onaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobukazu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Hoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kuboki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9035-3106","authenticated-orcid":false,"given":"Makoto","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"issue":"3","key":"2785_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"2785_CR2","unstructured":"El-Naggar AK, Chan JKC, Rubin Grandis J, Takata T, Slootweg PJ (2017) WHO classification of head and neck tumours. World Health Organization classification of tumours, 4th edn. International Agency for Research on Cancer,"},{"issue":"7","key":"2785_CR3","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/s1368-8375(03)00097-6","volume":"39","author":"R Haddad","year":"2003","unstructured":"Haddad R, Colevas AD, Krane JF et al (2003) Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study Oral Oncol 39(7):724\u2013727. https:\/\/doi.org\/10.1016\/s1368-8375(03)00097-6","journal-title":"A phase II study Oral Oncol"},{"issue":"2","key":"2785_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1200\/jco.18.00545","volume":"37","author":"H Takahashi","year":"2019","unstructured":"Takahashi H, Tada Y, Saotome T et al (2019) Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma. J Clin Oncol 37(2):125\u2013134. https:\/\/doi.org\/10.1200\/jco.18.00545","journal-title":"J Clin Oncol"},{"key":"2785_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac080","author":"X Le","year":"2022","unstructured":"Le X, Baik C, Bauman J et al (2022) Larotrectinib treatment for patients with TRK fusion-positive salivary gland cancers. Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyac080","journal-title":"Oncologist"},{"issue":"7","key":"2785_CR6","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1158\/1078-0432.Ccr-21-3597","volume":"28","author":"GD Demetri","year":"2022","unstructured":"Demetri GD, De Braud F, Drilon A et al (2022) Updated Integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res 28(7):1302\u20131312. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-3597","journal-title":"Clin Cancer Res"},{"issue":"17","key":"2785_CR7","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1002\/cncr.33036","volume":"126","author":"GJ Hanna","year":"2020","unstructured":"Hanna GJ, Guenette JP, Chau NG et al (2020) Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. Cancer 126(17):3972\u20133981. https:\/\/doi.org\/10.1002\/cncr.33036","journal-title":"Cancer"},{"key":"2785_CR8","doi-asserted-by":"publisher","unstructured":"Ferrarotto R, Metcalf R, Rodriguez CP, Muzaffar J, Even C, Perez CA, Herpen CML-V, Oliva M, Xia B, Bowles DW, Popovtzer A, Winquist E, Wirth LJ, Hao D, Kang H, Hotte SJ, Stemmer SM, Mehra R, Worden FP, Ho AL (2022) Results of ACCURACY: a phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent\/metastatic (R\/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut). J Clin Oncol 40 (16_suppl):6046\u20136046. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.6046","DOI":"10.1200\/JCO.2022.40.16_suppl.6046"},{"issue":"10","key":"2785_CR9","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/s1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J et al (2020) Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21(10):1353\u20131365. https:\/\/doi.org\/10.1016\/s1470-2045(20)30445-9","journal-title":"Lancet Oncol"},{"key":"2785_CR10","doi-asserted-by":"publisher","unstructured":"Even C, Delord JP, Price KA, Nakagawa K, Oh DY, Burge M, Chung HC, Doi T, Fakih M, Takahashi S, Yao L, Jin F, Norwood K, Hansen AR (2022) Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study. Eur J Cancer 171:259\u2013268. https:\/\/doi.org\/10.1016\/j.ejca.2022.05.007","DOI":"10.1016\/j.ejca.2022.05.007"},{"key":"2785_CR11","doi-asserted-by":"publisher","unstructured":"Dalin MG, Watson PA, Ho AL, Morris LG (2017) Androgen Receptor Signaling in Salivary Gland Cancer. Cancers (Basel) 9 (2). https:\/\/doi.org\/10.3390\/cancers9020017","DOI":"10.3390\/cancers9020017"},{"key":"2785_CR12","doi-asserted-by":"publisher","unstructured":"van der Hulst RW, van Krieken JH, van der Kwast TH, Gerritsen JJ, Baatenburg de Jong RJ, Lycklama \u00e0 Nijeholt AA, Meinders AE (1994) Partial remission of parotid gland carcinoma after goserelin. Lancet 344 (8925):817. https:\/\/doi.org\/10.1016\/s0140-6736(94)92372-8","DOI":"10.1016\/s0140-6736(94)92372-8"},{"issue":"4","key":"2785_CR13","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/annonc\/mdx771","volume":"29","author":"C Fushimi","year":"2018","unstructured":"Fushimi C, Tada Y, Takahashi H et al (2018) A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol 29(4):979\u2013984. https:\/\/doi.org\/10.1093\/annonc\/mdx771","journal-title":"Ann Oncol"},{"issue":"5","key":"2785_CR14","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/hed.23940","volume":"38","author":"LD Locati","year":"2016","unstructured":"Locati LD, Perrone F, Cortelazzi B et al (2016) Clinical activity of androgen deprivation therapy in patients with metastatic\/relapsed androgen receptor-positive salivary gland cancers. Head Neck 38(5):724\u2013731. https:\/\/doi.org\/10.1002\/hed.23940","journal-title":"Head Neck"},{"issue":"3","key":"2785_CR15","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/hed.25035","volume":"40","author":"E Boon","year":"2018","unstructured":"Boon E, van Boxtel W, Buter J et al (2018) Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in The Netherlands. Head Neck 40(3):605\u2013613. https:\/\/doi.org\/10.1002\/hed.25035","journal-title":"Head Neck"},{"key":"2785_CR16","doi-asserted-by":"publisher","unstructured":"Viscuse PV, Price KA, Garcia JJ, Schembri-Wismayer DJ, Chintakuntlawar AV (2019) First Line androgen deprivation therapy vs. chemotherapy for patients with androgen receptor positive recurrent or metastatic salivary gland carcinoma-a retrospective study. Front Oncol 9:701. https:\/\/doi.org\/10.3389\/fonc.2019.00701","DOI":"10.3389\/fonc.2019.00701"},{"key":"2785_CR17","doi-asserted-by":"publisher","first-page":"175883592211195","DOI":"10.1177\/17588359221119538","volume":"14","author":"D Kawakita","year":"2022","unstructured":"Kawakita D, Nagao T, Takahashi H et al (2022) Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma. Ther Adv Med Oncol 14:17588359221119538. https:\/\/doi.org\/10.1177\/17588359221119538","journal-title":"Ther Adv Med Oncol"},{"issue":"36","key":"2785_CR18","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1200\/jco.21.00468","volume":"39","author":"LD Locati","year":"2021","unstructured":"Locati LD, Cavalieri S, Bergamini C et al (2021) Abiraterone acetate in patients with castration-resistant, androgen receptor-expressing salivary gland cancer: a phase II trial. J Clin Oncol 39(36):4061\u20134068. https:\/\/doi.org\/10.1200\/jco.21.00468","journal-title":"J Clin Oncol"},{"issue":"36","key":"2785_CR19","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1200\/jco.22.00229","volume":"40","author":"AL Ho","year":"2022","unstructured":"Ho AL, Foster NR, Zoroufy AJ et al (2022) Phase II study of enzalutamide for patients with androgen receptor-positive salivary gland cancers (Alliance A091404). J Clin Oncol 40(36):4240\u20134249. https:\/\/doi.org\/10.1200\/jco.22.00229","journal-title":"J Clin Oncol"},{"issue":"2","key":"2785_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/cncr.10647","volume":"95","author":"DJ Samson","year":"2002","unstructured":"Samson DJ, Seidenfeld J, Schmitt B et al (2002) Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 95(2):361\u2013376. https:\/\/doi.org\/10.1002\/cncr.10647","journal-title":"Cancer"},{"issue":"11","key":"2785_CR21","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","volume":"102","author":"L Klotz","year":"2008","unstructured":"Klotz L, Boccon-Gibod L, Shore ND et al (2008) The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 102(11):1531\u20131538. https:\/\/doi.org\/10.1111\/j.1464-410X.2008.08183.x","journal-title":"BJU Int"},{"issue":"20","key":"2785_CR22","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/jco.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology\/college of american pathologists clinical practice guideline focused update. J Clin Oncol 36(20):2105\u20132122. https:\/\/doi.org\/10.1200\/jco.2018.77.8738","journal-title":"J Clin Oncol"},{"issue":"3","key":"2785_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transpl 48(3):452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transpl"},{"key":"2785_CR24","volume-title":"Darolutamide for patients with androgen receptor positive salivary gland cancers (DISCOVARY): The results of phase 2 study of darolutamide monotherapy","author":"S Okano","year":"2023","unstructured":"Okano S, Tahara M, Imamura Y et al (2023) Darolutamide for patients with androgen receptor positive salivary gland cancers (DISCOVARY): The results of phase 2 study of darolutamide monotherapy. Paper presented at the ASCO annual meeting, Chicago, IL"},{"issue":"35","key":"2785_CR25","doi-asserted-by":"publisher","first-page":"59023","DOI":"10.18632\/oncotarget.19812","volume":"8","author":"S Takase","year":"2017","unstructured":"Takase S, Kano S, Tada Y et al (2017) Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification. Oncotarget 8(35):59023\u201359035. https:\/\/doi.org\/10.18632\/oncotarget.19812","journal-title":"Oncotarget"},{"issue":"4","key":"2785_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/j.1365-2559.2012.04252.x","volume":"61","author":"S Di Palma","year":"2012","unstructured":"Di Palma S, Simpson RH, Marchi\u00f2 C et al (2012) Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes. Histopathology 61(4):629\u2013643. https:\/\/doi.org\/10.1111\/j.1365-2559.2012.04252.x","journal-title":"Histopathology"},{"issue":"10","key":"2785_CR27","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41379-020-0576-2","volume":"33","author":"SA Mueller","year":"2020","unstructured":"Mueller SA, Gauthier M-EA, Blackburn J et al (2020) Molecular patterns in salivary duct carcinoma identify prognostic subgroups. Mod Pathol 33(10):1896\u20131909. https:\/\/doi.org\/10.1038\/s41379-020-0576-2","journal-title":"Mod Pathol"},{"key":"2785_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.humpath.2019.08.009","volume":"93","author":"T Santana","year":"2019","unstructured":"Santana T, Pavel A, Martinek P et al (2019) Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications. Hum Pathol 93:37\u201347. https:\/\/doi.org\/10.1016\/j.humpath.2019.08.009","journal-title":"Hum Pathol"},{"key":"2785_CR29","doi-asserted-by":"publisher","unstructured":"Kinoshita I, Kano S, Shimizu Y, Kiyota N, Tada Y, Ijichi K, Yamazaki T, Homma A, Ito YM, Ono K, Kobayashi K, Isoe T, Hatanaka Y, Tsuda H, Morinaga S, Matsuno Y, Dosaka-Akita H (2019) Phase II study of trastuzumab and docetaxel therapy in patients with HER2-positive recurrent and\/or metastatic salivary gland carcinoma. Cancer Res 79 (13). https:\/\/doi.org\/10.1158\/1538-7445.Am2019-ct137","DOI":"10.1158\/1538-7445.Am2019-ct137"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02785-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02785-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02785-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T06:19:46Z","timestamp":1753942786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02785-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2785"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02785-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original publication has been updated for removal of \u201c(242 words)\u201d in Abstract.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Tahara reports grants and personal fees from Ono Pharmaceutical and Bayer; and personal fees from MSD, BMS, Merck Biopharma, Pfizer, Rakuten Medical, Lilly, Boehringer Ingelheim, Eisai, Chugai Pharmaceutical, Daiichi-Sankyo, Janssen Pharmaceutical, Genmab, Astra Zeneca, Abbvie and Astellas, outside the submitted work. TE reports personal fees from Ono Pharmaceutical, Bayer, MSD, and Merck Biopharma outside the submitted work. SO reports personal fees from Ono Pharmaceutical, MSD, BMS, and Merck Biopharma outside the submitted work. TF reports honoraria for lectures from Amelieff Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study protocol was approved by the Institutional Ethical Committee of the National Cancer Center Hospital East (reference number 2016\u2013243). Written informed consent for participation was not required for this study, in accordance with national legislation and institutional requirements. Patients and their families were provided an opportunity to opt-out of the study in accordance with the policy of the Japanese government. The study was conducted in accordance with the principles laid down in the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}]}}